Project Grant R01CA269499
Award Date
7/1/22
Completion Date
6/30/27
Dollars Obligated
$471K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute awarded a $690,825 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Brigham & Women's Hospital Inc. in Boston, MA, with a project period from June 21, 2024 to May 31, 2029. The grant supports research to investigate a novel mechanism of immune evasion by cancer cells, with the goal of advancing immunotherapy approaches to treat cancer. The project leverages combinatorial applications of nanoscale technologies to target this mechanism. Brigham &...
This federal Cooperative Agreement award of $2,393,958.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research to understand the potential of the immune system for breast cancer prevention in BRCA mutation carriers. The key objectives of the project are to: 1) Determine the immune factors that induce responses in BRCA mutant breast glands, 2) Examine the characteristics of immune cells infiltrating BRCA mutant breast...
This federal Project Grant award, valued at $527,159.00 and provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports a research project focused on understanding the early stages of breast cancer development in individuals with BRCA1 gene mutations. The key goals are to: Investigate whether BRCA1-deficient luminal mammary cells acquire a fetal-like stem cell program via the SOX10 transcription factor, leading to increased cell plasticity and breast cancer...
The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $701,408 Project Grant (CFDA 93.395 - Cancer Treatment Research) to elucidate resistance mechanisms and enhance response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project aims to characterize the co-evolution of cancer and the immune system during immunotherapy by profiling DNA, RNA, and immune cell...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Health Research, Inc. provides $719,799.00 to conduct research to determine the impact of metabolic adaptations on the tumor microenvironment and immune response in metastatic triple-negative breast cancer (TNBC). The research aims to investigate the mechanisms by which the bifunctional enzyme PFKFB4 regulates metabolic and genetic plasticity in the hypoxic tumor microenvironment, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $238,722 to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair in the persistence of cancer cells and the development of acquired drug resistance. The key objectives are to: (1) examine persistence mechanisms in response to PARP inhibitor treatment in BRCA1/2-mutant cancer cells, (2) explore the role of the mutagenic DNA repair...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
The National Cancer Institute (NCI) awarded a $433,157 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Endeavor Health Clinical Operations, a division of Northshore University HealthSystem Research Institute, for a study titled "Lipid-Rich Macrophages at the Tumor-Adipose Interface: A New Target for Locally-Invasive Prostate Cancer Therapy." The 2-year project, beginning on July 18, 2024, will investigate the role of lipid-rich adipose tissue macrophages in prostate cancer...
This $640,583 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance the efficacy of immunotherapy against metastatic colorectal cancer (mCRC). The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells, which can boost the metabolic fitness and anti-tumor activity of these immune cells within the mCRC tumor microenvironment. The research will investigate the specific mechanisms by which PPARD activation...
This $693,781 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), aims to advance the understanding and treatment of cancers with mutations in the IDH1 gene. The key objectives are to: Further study how mutant IDH1 and the metabolite 2-hydroxyglutarate it produces enable cancer cells to evade the immune system, while IDH1 inhibitors can cause immune...